Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder associated with the loss of catecholaminergic neurons in several brain regions. The motor symptoms of the disease are related to degeneration of the midbrain dopaminergic neurons, which occurs some time after the disease has begun. Both the innate and adaptive immune systems appear to play a role in the neurodegenerative process, and may contribute to disease progression. Here we review the neuropathology of PD with attention focused on the involvement of the innate immune cells (microglia) and the adaptive immune cells (T lymphocytes). In addition, we discuss animal models of the disease with emphasis on a progressive rat model which allows a detailed analysis of how the immune system contributes to neurodegeneration both during early and late stages of degeneration. Finally, for the early detection and treatment of PD, we discuss immunotherapy approaches.
Keywords: Dopamine, glia, inflammation, MPTP, neurodegeneration, peptoids, T cells
Current Molecular Pharmacology
Title:Parkinson's Disease: A Role for the Immune System
Volume: 5
Author(s): Dwight C. German, Todd Eagar and Patricia K. Sonsalla
Affiliation:
Keywords: Dopamine, glia, inflammation, MPTP, neurodegeneration, peptoids, T cells
Abstract: Parkinson’s disease (PD) is a progressive neurodegenerative disorder associated with the loss of catecholaminergic neurons in several brain regions. The motor symptoms of the disease are related to degeneration of the midbrain dopaminergic neurons, which occurs some time after the disease has begun. Both the innate and adaptive immune systems appear to play a role in the neurodegenerative process, and may contribute to disease progression. Here we review the neuropathology of PD with attention focused on the involvement of the innate immune cells (microglia) and the adaptive immune cells (T lymphocytes). In addition, we discuss animal models of the disease with emphasis on a progressive rat model which allows a detailed analysis of how the immune system contributes to neurodegeneration both during early and late stages of degeneration. Finally, for the early detection and treatment of PD, we discuss immunotherapy approaches.
Export Options
About this article
Cite this article as:
C. German Dwight, Eagar Todd and K. Sonsalla Patricia, Parkinson's Disease: A Role for the Immune System, Current Molecular Pharmacology 2012; 5 (3) . https://dx.doi.org/10.2174/1874467211205030003
DOI https://dx.doi.org/10.2174/1874467211205030003 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design Other Drugs Acting on Nervous System Associated with QT-Interval Prolongation
Current Drug Safety Editorial (Thematic Issue: Ceramics, Nanotubes, Advanced Materials: Theoretical and Experimental Structure-Property Relationships Part IV)
Current Physical Chemistry Association Between Heart Rate Variability and Parkinson’s Disease: A Meta-analysis
Current Pharmaceutical Design Antipsychotic Use and Mortality Risk in Community-Dwelling Alzheimer’s Disease Patients: Evidence for a Role of Dementia Severity
Current Alzheimer Research Mood Disorders in Elderly Population: Neurostimulative Treatment Possibilities
Recent Patents on CNS Drug Discovery (Discontinued) Neurodegeneration with Dementia: From Fundamentals of Pathology to Clinical Imaging by MRI and SPECT.
Current Medical Imaging Role of Nanomedicines in Delivery of Anti-Acetylcholinesterase Compounds to the Brain in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Early Ischemic Blood Brain Barrier Damage: A Potential Indicator for Hemorrhagic Transformation Following Tissue Plasminogen Activator (tPA) Thrombolysis?
Current Neurovascular Research Potential Therapeutic Relevance of Adenosine A2B and A2A Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Mitochondrial Pharmaceutics: A New Therapeutic Strategy to Ameliorate Oxidative Stress in Alzheimer’s Disease
Current Aging Science Editorial: In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology Blood Brain Barrier in Hypoxic-Ischemic Conditions
Current Neurovascular Research Treating the Cognitive Deficits of Schizophrenia with Alpha4Beta2 Neuronal Nicotinic Receptor Agonists
Current Pharmaceutical Design microRNAs-based Predictor Factor in Patients with Migraine-ischemic Stroke
MicroRNA Protein Aggregation in Neurodegenerative Diseases: Insights from Computational Analyses
Current Bioinformatics Association of rs610932 and rs670139 Polymorphisms in the MS4A Gene Cluster with Alzheimer’s Disease: An Updated Meta-analysis
Current Alzheimer Research Early Intervention in Psychosis: Rationale, Results and Implications for Treatment of Adolescents at Risk
Adolescent Psychiatry Aporphines and Alzheimer’s Disease: Towards a Medical Approach Facing the Future
Current Medicinal Chemistry Non-Alcoholic Fatty Liver Disease and Vascular Disease
Current Vascular Pharmacology